Sugi Predict

Sugi Predict / Compounds / SCHEMBL1380649

SCHEMBL1380649

SCHEMBL1380649

CN1CCN(c2cc(NS(=O)(=O)c3ccccc3)cc3ccccc23)CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 10/20 0.63
▸ LMNA P02545 2/20 0.56
▸ SMN1; SMN2 Q16637 2/20 0.56
▸ PKM P14618 1/20 0.56
▸ HTR1A P08908 2/20 0.54
▸ HTR2A P28223 2/20 0.54
▸ HTR2C P28335 2/20 0.54
▸ HTR7 P34969 2/20 0.54
▸ DRD3 P35462 2/20 0.54
▸ CYP1A2 P05177 1/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ CYP2D6 P10635 1/20 0.49
▸ DRD2 P14416 1/20 0.49
▸ HTR1D P28221 1/20 0.49
▸ HTR1B P28222 1/20 0.49
▸ HTR1E P28566 1/20 0.49
▸ HTR1F P30939 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ ADRA1B P35368 1/20 0.49
▸ HTR2B P41595 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6047113 0.99 HTR6 (0.61) HTR6LMNASMN1; SMN2PKMHTR1A
SCHEMBL3622742 0.82 HTR6 (0.59) HTR6LMNASMN1; SMN2PKMHTR1A
Hydrochloric Acid SCHEMBL1377875 0.81 HTR6 (0.58) HTR6LMNASMN1; SMN2PKMHTR1A
SCHEMBL1381190 0.77 HTR3A (0.51) HTR6LMNASMN1; SMN2PKMHTR1A
SCHEMBL6972094 0.77 HTR6 (1.00) HTR6HTR1AHTR2AHTR2CHTR7
SCHEMBL14355853 0.75 MCOLN3 (0.71) HTR6LMNASMN1; SMN2PKMHTR1A
SCHEMBL19667058 0.75 POLB (0.69) HTR6LMNASMN1; SMN2PKMHTR1A
SCHEMBL7084057 0.74 HTR6 (0.67) HTR6LMNASMN1; SMN2PKMHTR1A
SCHEMBL5549209 0.74 HTR6 (0.44) HTR6LMNASMN1; SMN2HTR1AHTR2A
SCHEMBL6975625 0.73 HTR6 (0.78) HTR6SMN1; SMN2HTR1AHTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4731114-B2 — — 2011-07-20 — — JP claimed
US-20100222330-A1 New Compounds BIOVITRUM AB (SE) 2010-09-02 — — US claimed
US-7572787-B2 Substituted naphthalene sulfonamides BIOVITRUM AB (SE) 2009-08-11 — — US claimed
US-20070066600-A1 Compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2007-03-22 — — US claimed
EP-1412325-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES BIOVITRUM AB (SE) 2004-04-28 — — EP claimed
US-20030158202-A1 Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders PROXIMAGEN NEUROSCIENCE PLC (GB) 2003-08-21 — — US claimed
WO-2002100822-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES BIOVITRUM AB (SE) 2002-12-19 — — WO claimed
US-20100222330-A1 New Compounds BIOVITRUM AB (SE) 2010-09-02 — — US disclosed
US-7572787-B2 Substituted naphthalene sulfonamides BIOVITRUM AB (SE) 2009-08-11 — — US disclosed
US-20070066598-A1 Compounds BIOVITRUM AB, A SWEDEN CORPORATION 2007-03-22 — — US disclosed
US-20070066599-A1 New compounds BIOVITRUM AB, A SWEDEN CORPORATION 2007-03-22 — — US disclosed
US-20070066600-A1 Compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2007-03-22 — — US disclosed
US-7144883-B2 Bicyclic sulfonamide compounds BIOVITRUM AB (SE) 2006-12-05 — — US disclosed
EP-1412325-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES BIOVITRUM AB (SE) 2004-04-28 — — EP disclosed
US-20030158202-A1 Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders PROXIMAGEN NEUROSCIENCE PLC (GB) 2003-08-21 — — US disclosed
WO-2002100822-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES BIOVITRUM AB (SE) 2002-12-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066599-A1 New compounds SULT2A1, GPR119, STS HTR6 1659/4885LMNA 3860/4885SMN1; SMN2 389/4885
US-20070066598-A1 Compounds SULT2A1, STS, SLC5A2 HTR6 1213/4885LMNA 3321/4885SMN1; SMN2 248/4885
US-20030158202-A1 Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders SULT2A1, SULT1A1, SULT1E1 HTR6 2369/4885LMNA 3411/4885SMN1; SMN2 350/4885
US-20070066600-A1 Compounds SULT2A1, STS, SLC5A2 HTR6 1213/4885LMNA 3321/4885SMN1; SMN2 248/4885
US-20100222330-A1 New Compounds SULT2A1, GPR119, STS HTR6 1659/4885LMNA 3860/4885SMN1; SMN2 389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.